What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Chi-Med and Lilly Amend 2013 Agreement

Change in responsibilities for the development & commercialization, collaborations, and distribution of fruquintinib in multiple areas

Hutchison China MediTech has announced a change (“2018 Amendment”) to the 2013 License and Collaboration Agreement on fruquintinib with Lilly Shanghai, an affiliate of Eli Lilly and Company. 

 
The 2018 Amendment covers adjustments in the respective roles and responsibilities of Chi-Med and Lilly, in China, for the development and commercialization of fruquintinib in the areas of future life cycle planning and development, collaborations for co-development of fruquintinib with other third-party anti-cancer agents as well as promotion and distribution rights of fruquintinib.  

“Through this amendment, Chi-Med is stepping forward to take on greater responsibility in return for a broader role and a larger share of the future economic interest on fruquintinib,” commented Simon To, chairman of Chi-Med. “Lilly has been and will continue to be a most important partner for Chi-Med in bringing fruquintinib to as broad a patient population as possible and we share a common goal to maximize the commercial success of fruquintinib in China.” 

Under the terms of the 2013 Agreement, decision making on LCI development beyond the initial indications of third-line colorectal cancer (“CRC”), third-line non-small cell lung cancer (“NSCLC”) and second-line gastric cancer was controlled by Lilly. The majority of development costs for LCIs were to be paid by Lilly, with the minority by Chi-Med.

The 2018 Amendment now gives Chi-Med all planning, execution and decision making responsibilities for LCI development on fruquintinib in China. Chi-Med will pay all of the costs associated with fruquintinib LCI development in China.  In return for this investment of capital and resources, Lilly will pay Chi-Med a $20 million milestone upon approval of each fruquintinib LCI in China, for up to three LCIs, totaling up to $60 million in LCI approval milestone payments. Furthermore, upon the launch of the first LCI, the tiered royalty structure, payable by Lilly to Chi-Med on total molecule sales in China, has been raised from the range of 15-20% in the 2013 Agreement to a new level of 15-29% under the 2018 Amendment.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics